Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models.

ABSTRACT: Growing evidence demonstrates the key role of the gut microbiota in human health and disease. The recent success of microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on its potential in conditions associated with gut dysbiosis, such as acute graft-versus-host disease, intestinal bowel diseases, neurodegenerative diseases, or even cancer. However, the difficulty in defining a "good" donor as well as the intrinsic variability of donor-derived products' taxonomic composition limits the translatability and reproducibility of these studies. Thus, the pooling of donors' feces has been proposed to homogenize product composition and achieve higher taxonomic richness and diversity. In this study, we compared the metagenomic profile of pooled produc

SUBMITTER: Reygner J 

PROVIDER: S-EPMC11107171 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature